Immatics (IMTX) Current Deferred Revenue (2019 - 2025)
Immatics (IMTX) posted Current Deferred Revenue of $21.6 million for Q4 2025, down 27.78% sequentially from $29.9 million in Q3 2025, and down 43.75% YoY from $38.4 million in Q4 2024.
Immatics (IMTX) Current Deferred Revenue (2019 - 2025) Analysis & Trends
Immatics has reported Current Deferred Revenue for 7 years, with the latest figure at $21.6 million in Q4 2025.
- Quarterly Current Deferred Revenue fell 43.75% year-over-year to $21.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $21.6 million (down 43.75% YoY) and the FY2025 annual result came in at $20.9 million, down 46.1% from the prior year.
- Current Deferred Revenue declined to $21.6 million in Q4 2025 per IMTX's latest filing, from $29.9 million in the prior quarter.
- Over five years, Current Deferred Revenue peaked at $124.3 million in Q4 2023 and troughed at $21.6 million in Q4 2025.
- A 5-year average of $72.9 million and a median of $73.5 million in 2021 frame the typical range for Current Deferred Revenue.
- The sharpest annual moves came in 2023 and 2025: Current Deferred Revenue soared 87.56% in 2023, then slumped 70.74% in 2025.
- Over 5 years, Current Deferred Revenue stood at $112.8 million in 2021, then plunged by 41.26% to $66.3 million in 2022, then jumped by 87.56% to $124.3 million in 2023, then slumped by 69.13% to $38.4 million in 2024, then slumped by 43.75% to $21.6 million in 2025.
- According to Business Quant data, Current Deferred Revenue over the past three periods registered $21.6 million, $29.9 million, and $31.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Immatics | 1.27 Bn | 719.31 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 21.58 Mn |
| Sep 30, 2025 | 29.88 Mn |
| Jun 30, 2025 | 31.20 Mn |
| Mar 31, 2025 | 30.68 Mn |
| Dec 31, 2024 | 38.37 Mn |
| Sep 30, 2024 | 75.70 Mn |
| Jun 30, 2024 | 102.87 Mn |
| Mar 31, 2024 | 104.86 Mn |
| Dec 31, 2023 | 124.30 Mn |
| Sep 30, 2023 | 67.55 Mn |
| Jun 30, 2023 | 74.04 Mn |
| Mar 31, 2023 | 70.07 Mn |
| Dec 31, 2022 | 66.27 Mn |
| Sep 30, 2022 | 104.07 Mn |
| Jun 30, 2022 | 123.05 Mn |
| Mar 31, 2022 | 47.14 Mn |
| Dec 31, 2021 | 112.83 Mn |
| Sep 30, 2021 | 72.97 Mn |
| Jun 30, 2021 | 74.91 Mn |
| Mar 31, 2021 | 86.50 Mn |